Pruritus Market Size, Industry Share, Trends 2024-34

Pruritus

Pruritus Market Size, Industry Share, Trends 2024-34

¿Te ha gustado? post

Market Overview:

The pruritus market reached a value of US$ 6.0 Billion in 2023 and expected to reach US$ 7.8 Billion by 2034, exhibiting a growth rate (CAGR) of 2.42% during 2024-2034. The pruritus market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market’s performance in the seven major regions. Additionally, the report evaluates the performance of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in the report. This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone interested or involved in the pruritus market.

Request for a sample of this report: https://www.imarcgroup.com/pruritus-market/requestsample

Pruritus Market Trends:

Pruritus, or itching, refers to an unpleasant sensation or feeling on the skin that provokes the desire to scratch. The pruritus market is expanding rapidly, owing to several key factors. Primarily, the market is driven by the increasing prevalence of chronic skin conditions like atopic dermatitis, psoriasis, and eczema, as well as the rising number of patients with systemic diseases that induce pruritus, such as end-stage renal disease (ESRD) and cholestasis. Advancements in understanding the pathophysiology of pruritus, particularly the role of neuroimmune interactions and itch-specific signaling pathways, have spurred the development of targeted therapies, including selective kappa-opioid receptor agonists, H4 receptor antagonists, and neurokinin-1 receptor antagonists. Additionally, the expansion of telemedicine and digital health solutions has heightened access to dermatological consultations, further boosting the growth of the pruritus market.

Increasing investments in R&D by pharmaceutical companies have led to the development of innovative treatments that address both the symptoms and the underlying causes of chronic pruritus. Moreover, the growing adoption of biologics and monoclonal antibodies, such as IL-4 and IL-13 inhibitors for pruritus associated with inflammatory skin diseases, is transforming the therapeutic landscape. Rising awareness of pruritus as a debilitating symptom, along with improved diagnostic tools, is encouraging earlier identification and treatment of underlying conditions. Consequently, the trend toward developing personalized therapies based on the underlying etiology of pruritus is anticipated to drive the growth of the pruritus market in the coming years.

Countries Covered:

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country:

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the pruritus market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the pruritus market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs

This report also provides a detailed analysis of the current graft vs host disease market drugs and late-stage pipeline drugs.

In-Market Drugs:

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

  • Drug overview
  • Mechanism of action
  • Regulatory status
  • Clinical trial results
  • Drug uptake and market performance

Competitive Landscape with key players:

The competitive landscape of the pruritus market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these Key Players:

  • Cara Therapeutics
  • Mirum Pharmaceuticals
  • Albireo Pharma
  • Chugai Pharmaceutical
  • Escient Pharmaceuticals
  • Regeneron
  • GlaxoSmithKline
  • MC2 Therapeutics

Ask Analyst for Customization and Explore Full Report with TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=7292&flag=C

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

Sin comentarios

Escribe un comentario